Organon & Co. (NYSE:OGN) Given Consensus Recommendation of “Reduce” by Analysts

Organon & Co. (NYSE:OGN) has been assigned a consensus recommendation of “Reduce” from the seven ratings firms that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $11.40.

Separately, Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 3rd.

Organon & Co. Stock Performance

Shares of NYSE:OGN traded up $0.01 on Friday, reaching $13.70. The company’s stock had a trading volume of 342,617 shares, compared to its average volume of 5,482,409. The stock’s 50-day moving average is $13.64 and its two-hundred day moving average is $11.72. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.78. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The stock has a market capitalization of $3.60 billion, a P/E ratio of 17.79, a PEG ratio of 1.27 and a beta of 1.52.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Organon & Co.’s dividend payout ratio (DPR) is currently 10.39%.

Institutional Trading of Organon & Co.

Institutional investors and hedge funds have recently made changes to their positions in the company. Private Management Group Inc. raised its holdings in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after acquiring an additional 1,204,979 shares during the period. First Trust Advisors LP lifted its holdings in shares of Organon & Co. by 78.1% in the first quarter. First Trust Advisors LP now owns 3,227,320 shares of the company’s stock valued at $19,332,000 after purchasing an additional 1,415,239 shares in the last quarter. Kahn Brothers Group Inc. purchased a new stake in Organon & Co. in the 2nd quarter worth about $36,159,000. Principal Financial Group Inc. boosted its position in Organon & Co. by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 1,260,689 shares of the company’s stock worth $7,552,000 after acquiring an additional 25,495 shares during the period. Finally, Groupe la Francaise acquired a new stake in Organon & Co. during the 2nd quarter worth about $10,499,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company focused on improving the health and well-being of women throughout their lives. Its women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as fertility treatments and medicines used in reproductive health.

The company also markets biosimilars and a portfolio of established medicines across areas including cardiovascular disease, respiratory conditions, dermatology, pain management and allergy. Its products are distributed in markets around the world, with a particular focus on expanding access to medicines in international and emerging markets.

Organon was established as an independent company through a spin-off from Merck & Co in June 2021.